SEC Form 4 · accession 0001209191-16-095658
TriVascular Technologies, Inc. · TRIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Paul Scopa
Director
Period of report
Feb 3, 2016
Accepted (ET)
Feb 4, 2016 · 1:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001432732
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 3, 2016 | D | 1,776,692 | — | D | 0 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were held as follows: 1,665,193 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 64,151 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 47,348 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- F2These shares were disposed of pursuant to the merger agreement between the issuer and Endologix, Inc. (such transaction, the "Merger"). In connection with the closing of the Merger, the reporting person received 0.631 share of Endologix common stock and $0.34 in cash for each share of issuer common stock held by such reporting person, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016.